폐암 게놈 검사 시장 : 기술별, 검사 종별, 용도별, 최종 사용자별 - 시장 예측(2026-2032년)

The Lung Cancer Genomic Testing Market was valued at USD 1.16 billion in 2025 and is projected to grow to USD 1.26 billion in 2026, with a CAGR of 8.58%, reaching USD 2.07 billion by 2032.

A comprehensive orientation to how technological advances and clinical integration are redefining lung cancer genomic testing and shaping care pathways

Lung cancer genomic testing now sits at the intersection of clinical urgency and technological capability, reshaping diagnostics, therapeutic decision-making, and translational research. As molecular insights increasingly determine targeted therapies and immunotherapy candidacy, clinicians and laboratories are adopting genomic assays to move from histology-based care to precision-guided treatment pathways. In consequence, previously discrete disciplines-pathology, molecular biology, bioinformatics, and clinical oncology-are converging to deliver integrated care pathways that reduce time to targeted therapy and enable more nuanced patient stratification.

Moreover, the testing landscape is evolving from single-gene assays to multi-gene panels and comprehensive genomic profiling that capture actionable mutations, copy number alterations, and complex genomic signatures. Complementing tissue-based approaches, minimally invasive alternatives such as blood-based testing are accelerating diagnostic workflows and improving patient access to serial monitoring. At the same time, regulatory clarity, payer engagement, and clinical guideline updates are beginning to align, making genomic testing a central component of standard care in many oncology networks. Taken together, these dynamics have created a new operating environment where technological differentiation, evidence generation, and operational resilience determine which organizations lead the next wave of clinical and commercial adoption.

How converging advances in sequencing, liquid biopsy, and digital bioinformatics are rapidly transforming diagnostic pathways and patient management in lung cancer care

The landscape of lung cancer genomic testing is undergoing several transformative shifts driven by advances in assay technology, data analytics, and care delivery models. Most notably, next generation sequencing has evolved from high-cost, research-oriented workflows toward more efficient, clinically validated platforms that support targeted sequencing panels as well as broader coverage through whole exome and whole genome approaches. This progression enables clinicians to detect rare variants and comprehensive genomic signatures while laboratories optimize throughput and turnaround time.

In parallel, liquid biopsy methodologies-encompassing both circulating tumor cells and circulating tumor DNA-are transitioning from complementary tools to integral components of diagnostic and monitoring strategies. These assays offer a less invasive route to capture tumor heterogeneity and to monitor treatment response or emergent resistance. Meanwhile, real time polymerase chain reaction and fluorescence in situ hybridization maintain important roles for specific, rapid biomarker detection, particularly where regulatory or payer frameworks favor established methods.

Concurrently, digital health and AI-driven bioinformatics have matured to support automated variant calling, clinical annotation, and decision support, thereby reducing interpretation bottlenecks and enabling scalable reporting across diverse clinical settings. Regulatory agencies are adapting guidance for companion diagnostics and complex genomic tests, and payers are increasingly evaluating clinical utility and value-based reimbursement pathways. Together, these shifts are creating a more integrated, data-rich ecosystem that rewards evidence generation, interoperability, and operational agility.

How recent tariff-driven supply chain pressures have reshaped procurement, manufacturing strategies, and commercial approaches for genomic diagnostics

Recent tariff adjustments enacted by national policymakers have introduced a renewed emphasis on supply chain resilience and procurement strategy within the diagnostic ecosystem. Because genomic testing relies on a global supply chain for reagents, sequencing instruments, plastic consumables, and specialized microfluidic components, any tariff-driven cost increases reverberate through laboratory operations, reagent procurement cycles, and capital equipment acquisition decisions. As a result, laboratories and diagnostic providers have had to reassess vendor contracts, inventory strategies, and capital planning to preserve service continuity and to maintain acceptable turnaround times.

In response, several stakeholders have explored alternative sourcing and local manufacturing partnerships to mitigate exposure to import levies and shipping volatility. Procurement teams are negotiating longer-term supply agreements and prioritizing suppliers with diversified production footprints to reduce single-source risk. At the same time, diagnostic developers are accelerating work on assay designs that reduce reagent volumes or substitute tariff-sensitive components, thereby lowering the operational impact of import duties.

From a clinical perspective, sustained cost pressure may slow the adoption of more expensive, comprehensive testing in some care settings unless offset by payer coverage or bundled contracting. Consequently, laboratories and device manufacturers are investing in health economic evidence and real-world utility studies to demonstrate cost-effectiveness and inform value-based arrangements. Overall, tariff-driven pressures are catalyzing a strategic reorientation toward supply-chain diversification, localized manufacturing, and commercially sustainable assay design.

Segment-focused insights showing how technology choices, specimen modalities, clinical applications, and end-user capabilities jointly determine adoption pathways and value propositions

A detailed segmentation perspective reveals nuanced adoption patterns across technology, test type, application, and end user categories that are shaping market opportunity and investment priorities. Within the technology dimension, assays range from fluorescence in situ hybridization and microarray platforms to real time polymerase chain reaction and Sanger sequencing; however, next generation sequencing has emerged as a pivotal technology with diverse configurations that include targeted sequencing panels for focused actionable alterations, whole exome sequencing for comprehensive coding-region analysis, and whole genome sequencing for the broadest possible variant detection and structural insight. Each configuration carries distinct trade-offs in sensitivity, breadth of coverage, turnaround time, and interpretive complexity.

Regarding test type, the domain divides between liquid biopsy and tissue biopsy modalities. Liquid biopsy comprises both circulating tumor cells and circulating tumor DNA approaches, offering minimally invasive sampling and superior feasibility for serial monitoring. Tissue biopsy remains essential for histopathologic assessment and includes fine needle aspiration techniques as well as traditional tissue sections used for immunohistochemistry and confirmatory molecular assays. These two sampling paradigms often play complementary roles in the diagnostic pathway, with diagnostic stewardship determining optimal sequencing of tests.

In terms of application, testing supports companion diagnostics that directly guide therapy selection, predictive testing to anticipate treatment response, prognostic testing to inform outcome expectations, and treatment monitoring to detect resistance or recurrence. Adoption intensity varies by clinical setting, evidence base, and payer alignment. Finally, end users encompass academic and research institutes that drive assay validation and translational studies, hospitals and diagnostic laboratories that deliver clinical testing at scale and manage patient workflows, and pharmaceutical and biotechnology companies that rely on robust genomic characterization to support drug development, companion diagnostic partnerships, and patient selection strategies. The interplay among these segments underscores the importance of tailored value propositions, from high-throughput clinical laboratory services to niche translational platforms supporting drug discovery.

Regionally differentiated adoption dynamics and infrastructure considerations that influence technology roll-out, reimbursement engagement, and strategic partnerships

Regional dynamics materially influence technology adoption, regulatory alignment, and commercial strategy, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a robust ecosystem of academic centers, integrated health systems, and diagnostic innovators has driven early clinical adoption of advanced genomic profiling and liquid biopsy testing. Reimbursement frameworks and large-scale clinical studies in this region have supported the integration of companion diagnostics into therapeutic pathways, while leading laboratories and commercial partners continue to invest in platform scalability and clinical validation programs.

Across Europe, the Middle East and Africa, the landscape is more heterogeneous, characterized by strong regulatory oversight in several countries alongside variability in access and infrastructure. European jurisdictions are increasingly harmonizing regulatory expectations for clinical evidence and companion diagnostics, and collaborative networks are advancing multicenter studies to address clinical utility questions. In contrast, access in some parts of the Middle East and Africa remains constrained by laboratory capacity and reimbursement barriers, prompting a focus on regional centers of excellence and public-private partnerships to extend advanced testing services.

In the Asia-Pacific region, rapid expansion in clinical capacity and manufacturing capabilities is evident alongside diverse payer environments. Several markets demonstrate high adoption rates for both sequencing platforms and liquid biopsy testing, supported by growing local diagnostics industries and targeted investments in genomics. Nevertheless, adoption is uneven, and strategic players often combine centralized high-complexity testing hubs with decentralized sample collection and digital reporting to bridge geographic and resource constraints. These regional distinctions underline the need for market entry strategies that reflect local regulatory processes, reimbursement pathways, and healthcare infrastructure.

How sequencing instrument makers, reagent suppliers, diagnostic laboratories, and biopharma partners are aligning strategies to gain clinical adoption and commercial differentiation

Competitive activity across the lung cancer genomic testing value chain is concentrated among companies that provide sequencing platforms, assay reagents, integrated diagnostic services, and clinical interpretation solutions, as well as among clinical laboratories and diagnostics developers who pair testing with therapeutic programs. Leading instrumentation providers have advanced platform roadmaps focused on throughput, run cost, and integrated analytics, while reagent and kit suppliers compete on robustness, lot-to-lot consistency, and clinical validation packages that simplify regulatory submissions and laboratory accreditation.

Diagnostic laboratories and specialty providers leverage vertical integration, offering end-to-end services from sample accessioning to clinical reporting, often augmenting their offerings with proprietary bioinformatics pipelines and curated variant databases. Pharmaceutical and biotechnology collaborators prioritize partners that can deliver rapid, reproducible genomic characterization to support patient selection in trials and companion diagnostic co-development. Strategic moves such as partnerships, distribution agreements, and targeted acquisitions are common as companies seek to broaden assay portfolios, enhance geographic footprint, and reduce time to market for diagnostic claims.

To remain competitive, organizations increasingly invest in real-world evidence generation, payor engagement, and interoperability with electronic health records to demonstrate clinical utility and to facilitate clinician adoption. Additionally, companies that offer scalable, cloud-enabled interpretation tools and that maintain high standards for clinical validation are best positioned to capture demand from both centralized reference laboratories and decentralized hospital networks.

Action-oriented recommendations for companies to strengthen supply resilience, accelerate evidence generation, and secure payer and partner alignment for sustainable growth

Industry leaders should prioritize a set of pragmatic, evidence-based actions to navigate technological complexity, policy shifts, and market pressures while capturing clinical and commercial value. First, diversify supply chains and pursue localized manufacturing or second-source agreements for tariff-sensitive reagents and consumables to reduce single-point vulnerabilities and to stabilize procurement costs. Parallel to this, invest in assay optimization that minimizes reagent volumes and streamlines workflows to preserve margins and resilience.

Second, accelerate clinical validation and real-world evidence programs that demonstrate clinical utility and health economic value. Robust outcome datasets will strengthen reimbursement negotiations and support placement of comprehensive genomic profiling in standard care pathways. Third, expand capabilities in bioinformatics and AI-driven interpretation to shorten report turnaround time, improve variant classification consistency, and enable scalable clinical decision support that integrates with electronic health systems. Fourth, cultivate payer relationships and explore value-based contracting that ties reimbursement to demonstrable clinical outcomes, thereby aligning incentives across stakeholders.

Fifth, form strategic partnerships with pharmaceutical developers to co-develop companion diagnostics and to secure trial enrollment through biomarker-driven screening. Finally, tailor market access strategies regionally by aligning product claims and evidence packages with local regulatory expectations and by deploying hybrid models that combine centralized high-complexity testing with facilitated sample logistics and remote reporting to broaden access.

A transparent multi-method research approach combining primary expert engagement and systematic evidence review to ensure rigorous and actionable insights

The research underlying this analysis employed a multi-method approach that combined primary qualitative inquiry with systematic secondary intelligence to build a robust and triangulated evidence base. Primary research included structured interviews with clinical laboratory directors, molecular pathologists, reimbursement specialists, diagnostic developers, and pharmaceutical R&D leaders, supplemented by expert panel discussions to validate emerging trends and practical challenges in assay deployment. These engagements provided granular insight into laboratory workflows, procurement dynamics, and the operational impact of regulatory and tariff changes.

Secondary research entailed a rigorous review of regulatory guidance documents, clinical practice recommendations, peer-reviewed literature on assay performance and utility, and corporate disclosures that elucidate strategic priorities and product capabilities. Data synthesis prioritized high-quality clinical validation studies and real-world evidence where available. All findings were cross-validated through triangulation to reconcile differing perspectives and to ensure that conclusions reflect consistent signals rather than isolated observations.

Where appropriate, analytical safeguards were applied to account for variability in care settings and regional policy environments. Methodological limitations were explicitly noted, particularly where evidence remains nascent or practice patterns are rapidly evolving. The research adhered to ethical standards for expert engagement and data handling, ensuring confidentiality and the integrity of qualitative insights.

A concise synthesis of how technological advances and strategic imperatives must be aligned to translate genomic testing into durable clinical and commercial impact

The convergence of advanced sequencing technologies, liquid biopsy innovations, and digital interpretation tools has irreversibly altered the clinical landscape for lung cancer genomic testing. These developments present both opportunities and challenges: opportunities to enable more precise treatment selection, to support adaptive clinical trials, and to deliver longitudinal monitoring with minimally invasive tests; and challenges in supply-chain management, evidence generation, and payer engagement that require strategic foresight. Decision-makers must therefore adopt an integrated view that aligns technological investment, clinical validation, and commercial pathways.

Effective responses will blend operational resilience with evidence-led commercialization. By diversifying supply sources, investing in compact and cost-efficient assays, and demonstrating clinical and economic value through robust studies, stakeholders can reduce exposure to policy and market shocks while accelerating adoption. At the same time, regionally nuanced strategies that respect local regulatory norms and healthcare infrastructures will be essential for converting global potential into sustainable clinical impact. In sum, the era of precision oncology in lung cancer depends on harmonized action across industry, clinical, and regulatory stakeholders to translate technical capability into improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Genomic Testing Market, by Technology

• 8.1. Fluorescence In Situ Hybridization
• 8.2. Microarray
• 8.3. Next Generation Sequencing
  • 8.3.1. Targeted Sequencing
  • 8.3.2. Whole Exome Sequencing
  • 8.3.3. Whole Genome Sequencing
• 8.4. Real Time Polymerase Chain Reaction
• 8.5. Sanger Sequencing

9. Lung Cancer Genomic Testing Market, by Test Type

• 9.1. Liquid Biopsy
  • 9.1.1. Circulating Tumor Cells
  • 9.1.2. Circulating Tumor Dna
• 9.2. Tissue Biopsy
  • 9.2.1. Fine Needle Aspiration
  • 9.2.2. Tissue Section

10. Lung Cancer Genomic Testing Market, by Application

• 10.1. Companion Diagnostics
• 10.2. Predictive Testing
• 10.3. Prognostic Testing
• 10.4. Treatment Monitoring

11. Lung Cancer Genomic Testing Market, by End User

• 11.1. Academic And Research Institutes
• 11.2. Hospitals And Diagnostic Laboratories
• 11.3. Pharmaceutical And Biotechnology Companies

12. Lung Cancer Genomic Testing Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Lung Cancer Genomic Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Lung Cancer Genomic Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Lung Cancer Genomic Testing Market

16. China Lung Cancer Genomic Testing Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. Admera Health
• 17.7. Agilent Technologies, Inc.
• 17.8. BGI
• 17.9. CD Genomics
• 17.10. CeGaT GmbH
• 17.11. Centogene N.V.
• 17.12. F. Hoffmann-La Roche AG
• 17.13. Illumina, Inc.
• 17.14. Laboratory Corporation of America Holdings
• 17.15. NeoGenomics Laboratories
• 17.16. OncoDNA
• 17.17. OPKO Health, Inc.
• 17.18. QIAGEN N.V.
• 17.19. Quest Diagnostics Incorporated
• 17.20. Thermo Fisher Scientific, Inc.
• 17.21. Veracyte, Inc.